Aduro Biotech (ADRO) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research Published on October 23,2018

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

• ADRO Quick QuoteADROPositive Net Change

• consensus-outlook
• earnings
• earnings-consensus
• earnings-esp
• earnings-estimates-revisions
• earnings-expectations
• earnings-preview
• stock-price-change
• zacks-consensus-estimate

Implied Volatility Surging for Aduro BioTech (ADRO) Stock Options

by Zacks Equity Research Published on September 19,2018

Aduro BioTech (ADRO) needs investors to pay close attention to the stock based on moves in the options market lately.

• ADRO Quick QuoteADROPositive Net Change

Aduro's Cancer Arm & Strong Collaborations Boost Growth

by Zacks Equity Research Published on September 18,2018

Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

• JNJ Quick QuoteJNJPositive Net Change
• NVS Quick QuoteNVSPositive Net Change
• BMY Quick QuoteBMYNegative Net Change
• ADRO Quick QuoteADROPositive Net Change

Aduro Biotech (ADRO) Up 17.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on August 31,2018

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• ADRO Quick QuoteADROPositive Net Change

Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research Published on August 03,2018

Aduro's loss (ADRO) betters estimates in Q2. However, lower license and collaboration fees induce a slight dip in year-over-year revenues.

• NVS Quick QuoteNVSPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• ADRO Quick QuoteADROPositive Net Change

Aduro Biotech (ADRO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on August 01,2018

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.06% and -29.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

• ADRO Quick QuoteADROPositive Net Change

Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?

by Zacks Equity Research Published on July 31,2018

On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.

• DRNA Quick QuoteDRNAPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• ACAD Quick QuoteACADPositive Net Change
• PCRX Quick QuotePCRXNegative Net Change

What's in Store for Adverum (ADVM) This Earnings Season?

by Zacks Equity Research Published on July 31,2018

On Adverum's (ADVM) second-quarter 2018 conference call, investor focus will be on the company's progress with its pipeline candidates.

• REGN Quick QuoteREGNPositive Net Change
• DRNA Quick QuoteDRNAPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• ADVM Quick QuoteADVMPositive Net Change

What's in the Cards for Conatus (CNAT) This Earnings Season?

by Zacks Equity Research Published on July 30,2018

On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.

• NVS Quick QuoteNVSPositive Net Change
• CNAT Quick QuoteCNATPositive Net Change
• BDSI Quick QuoteBDSIPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?

by Zacks Equity Research Published on July 30,2018

On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.

• AGIO Quick QuoteAGIOPositive Net Change
• CELG Quick QuoteCELGPositive Net Change
• BDSI Quick QuoteBDSIPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research Published on July 30,2018

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

• BDSI Quick QuoteBDSIPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• TEVA Quick QuoteTEVAPositive Net Change
• MYL Quick QuoteMYLPositive Net Change

BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 30,2018

BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales in the second quarter. On the call, management is likely to comment on the launch preparation for pegvaliase.

• PFE Quick QuotePFENegative Net Change
• BMRN Quick QuoteBMRNPositive Net Change
• BDSI Quick QuoteBDSIPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

Why is Aduro (ADRO) Up 18.6% Since Its Last Earnings Report?

by Zacks Equity Research Published on June 01,2018

Aduro (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• ADRO Quick QuoteADROPositive Net Change

Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research Published on May 04,2018

Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.

• NVS Quick QuoteNVSPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• LGND Quick QuoteLGNDPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research Published on March 05,2018

Aduro (ADRO) reports narrower-than-expected loss in Q4. However, sales miss estimates and fall year over year on declining grant revenues.

• NVS Quick QuoteNVSPositive Net Change
• REGN Quick QuoteREGNPositive Net Change
• LGND Quick QuoteLGNDPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

Will Global Industrial Unit Aid Ecolab (ECL) in Q4 Earnings?

by Zacks Equity Research Published on February 12,2018

Ecolab's (ECL) strong segmental sales and acquisition-driven strategies are likely to drive fourth-quarter results.

• ECL Quick QuoteECLNegative Net Change
• AMPH Quick QuoteAMPHPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

Henry Schein (HSIC) Q4 Earnings to Show Growth in All Lines?

by Zacks Equity Research Published on February 12,2018

Henry Schein (HSIC) likely to gain on strength across all business segments in Q4.

• AMPH Quick QuoteAMPHPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• HSIC Quick QuoteHSICPositive Net Change

Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss

by Zacks Equity Research Published on November 01,2017

Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.

• BMY Quick QuoteBMYNegative Net Change
• NVS Quick QuoteNVSPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• ADRO Quick QuoteADROPositive Net Change

Celgene Down on Discontinued Crohn's Disease Drug Study

by Zacks Equity Research Published on October 20,2017

Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.

• AZN Quick QuoteAZNPositive Net Change
• MRK Quick QuoteMRKNegative Net Change
• CELG Quick QuoteCELGPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge

by Zacks Equity Research Published on October 13,2017

AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.

• LGND Quick QuoteLGNDPositive Net Change
• ADAP Quick QuoteADAPPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• ACRX Quick QuoteACRXPositive Net Change

Adverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher

by Zacks Equity Research Published on October 13,2017

Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

• ADRO Quick QuoteADROPositive Net Change
• ADVM Quick QuoteADVMPositive Net Change

Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017

by Zacks Equity Research Published on October 12,2017

Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.

• CELG Quick QuoteCELGPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• ACAD Quick QuoteACADPositive Net Change
• ICPT Quick QuoteICPTPositive Net Change

Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel

by Zacks Equity Research Published on October 10,2017

Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.

• CELG Quick QuoteCELGPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• ACAD Quick QuoteACADPositive Net Change

Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

by Zacks Equity Research Published on October 10,2017

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

• NVO Quick QuoteNVONegative Net Change
• BAYRY Quick QuoteBAYRYPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• ACAD Quick QuoteACADPositive Net Change

Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up

by Zacks Equity Research Published on October 09,2017

Flexion Therapeutics (FLXN) announced that its non-opioid intra-articular injection for treating knee pain has received FDA approval.

• SNY Quick QuoteSNYPositive Net Change
• ADAP Quick QuoteADAPPositive Net Change
• ADRO Quick QuoteADROPositive Net Change
• FLXN Quick QuoteFLXNPositive Net Change